Septerna (NASDAQ:SEPN) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Septerna (NASDAQ:SEPN) from a buy rating to a hold rating in a research report report published on Saturday.

Several other equities research analysts have also commented on SEPN. HC Wainwright raised their price target on shares of Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research report on Thursday, January 22nd. Raymond James Financial began coverage on Septerna in a report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price objective for the company. JonesTrading began coverage on Septerna in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 target price on the stock. Finally, Truist Financial lifted their target price on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Septerna currently has an average rating of “Moderate Buy” and an average target price of $44.00.

Septerna Stock Performance

Septerna stock opened at $25.14 on Friday. Septerna has a one year low of $4.66 and a one year high of $32.63. The company has a 50-day simple moving average of $26.78 and a 200-day simple moving average of $23.46. The firm has a market capitalization of $1.13 billion, a P/E ratio of -22.65 and a beta of 3.46.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The firm had revenue of $24.12 million during the quarter, compared to the consensus estimate of $20.44 million. Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. As a group, sell-side analysts forecast that Septerna will post -7.11 earnings per share for the current year.

Insider Transactions at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total value of $115,880.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at $5,046,834.73. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Samira Shaikhly sold 70,453 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the transaction, the insider owned 793 shares in the company, valued at $22,283.30. This represents a 98.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Septerna

A number of institutional investors have recently added to or reduced their stakes in SEPN. Group One Trading LLC increased its position in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the period. Global Retirement Partners LLC bought a new stake in shares of Septerna in the 4th quarter worth $35,000. Russell Investments Group Ltd. acquired a new stake in shares of Septerna in the third quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna in the fourth quarter valued at $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Septerna during the fourth quarter valued at about $61,000.

More Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $40.00 price target on SEPN, signaling continued analyst conviction in the company’s longer‑term upside despite the cuts. MarketBeat SEPN page
• Neutral Sentiment: Coverage roundup: a Globe and Mail piece highlights mixed analyst views on several tech names including Septerna, underscoring market disagreement about timing and magnitude of recovery. Analysts Conflicted on These Technology Names
• Neutral Sentiment: HC Wainwright published multi‑quarter 2027 EPS projections (Q1–Q4 2027 and FY2027), providing a forward framework for the next fiscal year but not materially changing the firm’s Buy stance. MarketBeat SEPN page
• Negative Sentiment: HC Wainwright cut Q1–Q4 2026 quarter estimates (Q1 to ($0.46), Q2 to ($0.55), Q3 to ($0.62), Q4 to ($0.70)), lowering FY2026 EPS to ($2.34) from ($1.67). The downward revisions widen expected near‑term losses and create pressure on sentiment. MarketBeat SEPN page

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.